The global biosimilars market is expected to reach $35 billion by 2030. Their uptake though faces considerable challenges in context to regulatory uncertainty, production complexity, interchangeability and competition. At IBC Asia’s 9th Annual Biosimilars Asia, top industry players will come together to explore tactics for overcoming hurdles unique to biosimilars in China, and globally. A focus on partnerships and commercial opportunities will be complemented by insights on disruptive technologies in manufacturing, commercialisation, risk management and pharma co-vigilance.
2017 Attendees List
- 300+ Companies, 70+ speakers, 60+ Sessions
- Unparalleled learning and targeted networking across three (3) co-located events
- Assess global potential in the biosimilars market
- Review the attractiveness of China as a continued investment destination
- Developments in regulatory pathways and approvals in China
- Examine advances in Innovation & Technology for Biosimilar Development
- Optimise development strategies and production capabilities to ensure high product quality and stay ahead of competition
- Preview latest equipment and technologies and hear from top vendors on how they are partnering with your peers
Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.
Vice President, Manufacturing, Innovent Biologics, China
SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd., China
Managing Partner, Quadria Capital Investment Management Pte Ltd, Singapore
CIO, livzon Pharmaceutical Group, China
Dr. Christopher J. Hickey
Senior Director Government Affairs, Market Access & Communications, Pfizer
Senior Representative, Kerry Inc., U.S.
Dr. Scott Liu
President and CEO, Shanghai Henlius Biotech Inc.
Senior Vice President, Medical & Scientific Strategy, Syneos Health
Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu Aosaikang Pharmaceutical Co Ltd, China
Dr. Jacqueline Ming Liu
Vice President, TOT Biopharma, China
Dr Qiwei Wu
Ph.D, Vice President of Process Development and Manufacturing, Livzon Mabpharma
Dr Amy Hong Que
Vice President - Quality, Innovent Biologics
Dr. Li Shi
Chief Executive Officer, Shanghai Zerun Biotech Co. Ltd
Prof. Dr. Florian Turk
Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals Sandoz International GmbH, Germany
Associate Vice President, Division of Project Development, Mycenax Biotech Inc., Taiwan
Vice President of Business Development, Samsung Bioepis, Korea
Dr. Xin Zhang
Head of Global Clinical Operations and Affairs, Shanghai Henlius Biotech Co Ltd, China
Director, Product Development, Zumutor Biologics, India
Team Leader of R&D CMC/PM, Celltrion R&D, Korea
General Manager - Business Development & Licensing, Intas Pharmaceuticals, India
China Biosimilars Regulation Publishing Manager, Pfizer
Assistant Director, WuXi Biologics
M.Sc. Vice President Head of CMC General Manager, Generon Beijing, China
Senior Vice President and Chief Medical Officer - Global Clinical Operations and Affairs, Shanghai Henlius Biotech Co Ltd, China
President, I-Mab Biopharma, China
Business Development Manager, Pall Life Sciences, UK
Still have a question?